Description
Description: This assay employs a two-site sandwich ELISA to quantitate CHRDL1 in samples. An antibody specific for CHRDL1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and any CHRDL1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for CHRDL1 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of CHRDL1 bound in the initial step. The color development is stopped and the intensity of the color is measured.
Overview: In the visual system, the establishment of the anteroposterior and dorsoventral axes in the retina and tectum during development is important for topographic retinotectal projection.Ventroptin, an antagonist of bone morphogenic protein-4, which is mainly expressed in the ventral retina, not only with a ventral high-dorsal low gradient but also with a nasal high-temporal low gradient at later stages. Misexpression of ventroptin altered expression patterns of several topographic genes in the retina and projection of the retinal axons to the tectum along both axes. Thus, the topographic retinotectal projection appears to be specified by the double-gradient molecule ventroptin along the 2 axes. The chick ventroptin protein contains a putative signal peptide and 3 cysteine-rich repeats